Time To Worry? Analysts Just Downgraded Their Concord Biotech Limited (NSE:CONCORDBIO) Outlook
One thing we could say about the analysts on Concord Biotech Limited (NSE:CONCORDBIO) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well. Shares are up 9.1% to ₹1,272 in the past week. It will be interesting to see if this downgrade motivates investors to start selling their holdings.
Following the downgrade, the current consensus from Concord Biotech's five analysts is for revenues of ₹13b in 2027 which - if met - would reflect a meaningful 19% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of ₹14b in 2027. The consensus view seems to have become more pessimistic on Concord Biotech, noting the substantial drop in revenue estimates in this update.
See our latest analysis for Concord Biotech
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Concord Biotech's past performance and to peers in the same industry. The analysts are definitely expecting Concord Biotech's growth to accelerate, with the forecast 19% annualised growth to the end of 2027 ranking favourably alongside historical growth of 11% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 11% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Concord Biotech to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that analysts cut their revenue estimates for this year. They're also forecasting more rapid revenue growth than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Concord Biotech going forwards.
Thirsting for more data? We have estimates for Concord Biotech from its five analysts out until 2029, and you can see them free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.